Compare LEDS & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LEDS | LSTA |
|---|---|---|
| Founded | 2005 | 1980 |
| Country | Taiwan | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Misc Health and Biotechnology Services |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.3M | 20.9M |
| IPO Year | 2010 | N/A |
| Metric | LEDS | LSTA |
|---|---|---|
| Price | $1.85 | $2.04 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $23.50 |
| AVG Volume (30 Days) | 31.1K | ★ 32.8K |
| Earning Date | 01-09-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $43,009,000.00 | $1,070,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 729.81 | N/A |
| 52 Week Low | $1.20 | $1.81 |
| 52 Week High | $3.37 | $4.20 |
| Indicator | LEDS | LSTA |
|---|---|---|
| Relative Strength Index (RSI) | 36.18 | 43.33 |
| Support Level | $1.71 | $1.85 |
| Resistance Level | $2.43 | $2.17 |
| Average True Range (ATR) | 0.19 | 0.17 |
| MACD | -0.07 | 0.01 |
| Stochastic Oscillator | 15.48 | 47.76 |
SemiLEDs Corp develops, manufactures, and sells light-emitting diode chips and LED components. The company's products include LED Chips, LED Components, and Lighting Products. Its products are used for general lighting applications, including street lights and commercial, industrial, system, and residential lighting; specialty industrial applications, such as ultraviolet, or Ultraviolet, curing of polymers, LED light therapy in medical/cosmetic applications, counterfeit detection, LED lighting for horticulture applications, architectural lighting and entertainment lighting. Substantial revenue is generated from the sale of LED components products. Geographically, it derives a majority of its revenue from Japan.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The group has one operating segment, the research and development of its investigational drug product.